XML 46 R30.htm IDEA: XBRL DOCUMENT v3.23.3
Fair value measurement
12 Months Ended
Jun. 30, 2023
Text block [abstract]  
Fair value measurement
Note 2
5
. Fair value measurement
Fair value hierarchy
The following tables detail the consolidated entity’s assets and liabilities, measured or disclosed at fair value, using a three level hierarchy, based on the lowest level of input that is significant to the entire fair value measurement, being:
Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date
Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly
Level 3: Unobservable inputs for the asset or liability
 
Consolidated - 2023
  
Level 1
A$’000
    
Level 2
A$’000
    
Level 3
A$’000
    
Total
A$’000
 
         
Liabilities
                                   
Contingent Consideration
     —          —          1,404        1,404  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total liabilities
     —          —          1,404        1,404  
    
 
 
    
 
 
    
 
 
    
 
 
 
         
Consolidated - 2022
                           
         
Liabilities
                                   
Contingent Consideration
     —          —          1,168        1,168  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total liabilities
     —          —          1,168        1,168  
    
 
 
    
 
 
    
 
 
    
 
 
 
There were no transfers between levels during the financial year.
The fair value of contingent consideration related to the acquisition of Glioblast Pty Ltd and the license agreement is estimated by probability-weighting the expected future cash outflows, adjusting for risk and discounting.
The effects on the fair value of risk and uncertainty in the future cash flows are dealt with by adjusting the estimated cash flows rather than adjusting the discount rate. The estimated cashflows were adjusted based on the directors’ assessment of achieving contracted milestones as disclosed in Note 1
9
. The probabilities used fell in the range of 57% to 60% and were informed by generally accepted industry probabilities of drugs achieving certain milestones in their progression towards registration.
Level 3 assets and liabilities
Movements in level 3 assets and liabilities during the current and previous financial year are set out below:
 
    
Level 3
A$’000
    
Total
A$’000
 
Consolidated
                 
Balance at 1 July 2021
     1,015        1,015  
Losses recognized in profit or loss
     153        153  
 
 
 
 
 
 
 
 
 
Balance at 30 June 2022
     1,168        1,168  
    
 
 
    
 
 
 
Losses recognized in profit or loss
     236        236  
    
 
 
    
 
 
 
Balance at 30 June 2023
     1,404        1,404